Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL536456 | 1.00 | ACHE (0.46) | ACHENAAACYP4F2CYP4A11GAA | |
| SCHEMBL1498093 | 1.00 | ACHE (0.46) | ACHENAAACYP4F2CYP4A11GAA | |
| SCHEMBL1498116 | 1.00 | ACHE (0.46) | ACHENAAACYP4F2CYP4A11GAA | |
| SCHEMBL3846617 | 1.00 | ACHE (0.46) | ACHENAAACYP4F2CYP4A11GAA | |
| SCHEMBL6060295 | 0.98 | ACHE (0.43) | ACHENAAACYP4F2CYP4A11GAA | |
| Myristyl Alcohol SCHEMBL23572569 | 0.92 | ACHE (0.53) | ACHENAAAALDH1A1TSHREPHX1 | |
| 1,4-Butanediol SCHEMBL6281294 | 0.92 | ACHE (0.53) | ACHENAAAALDH1A1TSHREPHX1 | |
| Cetyl Alcohol SCHEMBL27525642 | 0.92 | ACHE (0.53) | ACHENAAAALDH1A1TSHREPHX1 | |
| SCHEMBL3460925 | 0.91 | ACHE (0.36) | ACHEALDH1A1 | |
| SCHEMBL3482815 | 0.89 | GPR84 (0.55) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2705879-B1 | COMBINATION OF OILS FOR ANTIPERSPIRANT COMPOSITIONS WITH IMPROVED WHITE MARK PROTECTION | HENKEL AG & CO KGAA (DE) | 2017-06-07 | — | — | EP | disclosed |
| EP-2480192-B1 | NON-AEROSOL WATER-FREE ANTIPERSPIRANT IN WHICH ACTIVE SUBSTANCES ARE MORE READILY RELEASED | HENKEL AG & CO KGAA (DE) | 2016-01-13 | — | — | EP | disclosed |
| EP-2480193-B1 | NON-AEROSOL WATER-FREE ANTIPERSPIRANT IN WHICH ACTIVE SUBSTANCES ARE MORE READILY RELEASED | HENKEL AG & CO KGAA (DE) | 2015-08-19 | — | — | EP | disclosed |
| EP-2705879-A1 | COMBINATION OF OILS FOR ANTIPERSPIRANT COMPOSITIONS WITH IMPROVED WHITE MARK PROTECTION | Henkel AG&Co. KGAA (DE) | 2014-03-12 | — | — | EP | disclosed |
| US-20130345260-A1 | High Viscosity Liquid Controlled Delivery System and Medical or Surgical Device | DURECT CORPORATION (US) | 2013-12-26 | — | — | US | disclosed |
| US-7833543-B2 | Sustained release of active materials; storage stability | DURECT CORPORATION (US) | 2010-11-16 | — | — | US | disclosed |
| US-20080152708-A1 | High viscosity liquid controlled delivery system and medical or surgical device | DURECT CORPORATION | 2008-06-26 | — | — | US | disclosed |
| US-20080145419-A1 | High viscosity liquid controlled delivery system and medical or surgical device | DURECT CORPORATION | 2008-06-19 | — | — | US | disclosed |
| US-20060210599-A1 | Injectable or sprayable nonpolymeric ester or mixed ester solution easily formulated with therapeutic agents | GIBSON JOHN W | 2006-09-21 | — | — | US | disclosed |
| US-7053209-B1 | High viscosity liquid controlled delivery system and medical or surgical device | DURECT CORPORATION (US) | 2006-05-30 | — | — | US | disclosed |
| US-6413536-B1 | DELIVERING ACTIVE MATERIALS | SOUTHERN BIOSYSTEMS, INC. | 2002-07-02 | — | — | US | disclosed |
| US-4675177-A | ALUMINUM-ZIRCONIUM SALTS, LACTATE ESTERS OF LOWER ALKANOLS | AMERICAN CYANAMID COMPANY (US) | 1987-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060210599-A1 | Injectable or sprayable nonpolymeric ester or mixed ester solution easily formulated with therapeutic agents | MMP1, MMP11, MMP13 | ACHE 877/4885NAAA 1364/4885CYP4F2 2796/4885 |
| US-20080152708-A1 | High viscosity liquid controlled delivery system and medical or surgical device | MMP1, MMP13, MMP9 | ACHE 1432/4885NAAA 3453/4885CYP4F2 3941/4885 |
| US-20130345260-A1 | High Viscosity Liquid Controlled Delivery System and Medical or Surgical Device | MMP1, MMP13, MMP9 | ACHE 1463/4885NAAA 3401/4885CYP4F2 3912/4885 |
| US-20080145419-A1 | High viscosity liquid controlled delivery system and medical or surgical device | MMP1, MMP13, MMP9 | ACHE 1432/4885NAAA 3453/4885CYP4F2 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.